175 related articles for article (PubMed ID: 34655298)
21. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
Cao Y; Li X; Kong S; Shang S; Qi Y
J Cell Mol Med; 2020 May; 24(9):5135-5145. PubMed ID: 32277580
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
Braal CL; Jongbloed EM; Wilting SM; Mathijssen RHJ; Koolen SLW; Jager A
Drugs; 2021 Feb; 81(3):317-331. PubMed ID: 33369721
[TBL] [Abstract][Full Text] [Related]
23. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
Corona SP; Generali D
Drug Des Devel Ther; 2018; 12():321-330. PubMed ID: 29497278
[TBL] [Abstract][Full Text] [Related]
24. Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
Zhou Y; Shen JK; Yu Z; Hornicek FJ; Kan Q; Duan Z
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1573-1582. PubMed ID: 29452249
[TBL] [Abstract][Full Text] [Related]
25. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
26. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
27. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.
Teo ZL; Versaci S; Dushyanthen S; Caramia F; Savas P; Mintoff CP; Zethoven M; Virassamy B; Luen SJ; McArthur GA; Phillips WA; Darcy PK; Loi S
Cancer Res; 2017 Nov; 77(22):6340-6352. PubMed ID: 28947417
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma.
Chen D; Sun X; Zhang X; Cao J
Biomed Res Int; 2020; 2020():9525207. PubMed ID: 32626773
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):85-91. PubMed ID: 30577708
[TBL] [Abstract][Full Text] [Related]
30. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.
Torres-Guzmán R; Ganado MP; Mur C; Marugan C; Baquero C; Yang Y; Zeng Y; Bian H; Du J; de Dios A; Puig O; Lallena MJ
Oncotarget; 2022; 13():864-875. PubMed ID: 35813283
[TBL] [Abstract][Full Text] [Related]
31. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
32. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
Lee HJ; Lee WK; Kang CW; Ku CR; Cho YH; Lee EJ
Cancer Lett; 2018 Mar; 417():131-140. PubMed ID: 29306020
[TBL] [Abstract][Full Text] [Related]
33. The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.
Iriyama N; Hino H; Moriya S; Hiramoto M; Hatta Y; Takei M; Miyazawa K
Leuk Lymphoma; 2018 Jun; 59(6):1439-1450. PubMed ID: 28918692
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
Yuan Y; Wen W; Yost SE; Xing Q; Yan J; Han ES; Mortimer J; Yim JH
Sci Rep; 2019 May; 9(1):7509. PubMed ID: 31101835
[TBL] [Abstract][Full Text] [Related]
35. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
McClendon AK; Dean JL; Rivadeneira DB; Yu JE; Reed CA; Gao E; Farber JL; Force T; Koch WJ; Knudsen ES
Cell Cycle; 2012 Jul; 11(14):2747-55. PubMed ID: 22751436
[TBL] [Abstract][Full Text] [Related]
36. Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
El Hachem G; Gombos A; Awada A
Expert Rev Anticancer Ther; 2021 Jan; 21(1):81-92. PubMed ID: 33054442
[TBL] [Abstract][Full Text] [Related]
37. Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1.
Romero-Pozuelo J; Figlia G; Kaya O; Martin-Villalba A; Teleman AA
Cell Rep; 2020 Apr; 31(2):107504. PubMed ID: 32294430
[TBL] [Abstract][Full Text] [Related]
38. JHD205, A Novel Abemaciclib Derivative, Exerts Antitumor Effects on Breast Cancer by CDK4/6.
Ji J; Qin J; Wang X; Lv M; Hou X; Jing A; Zhou J; Zuo L; Liu W; Feng J; Qian Q; Liu Y; Wang X; Liu B
Anticancer Agents Med Chem; 2024; 24(6):400-411. PubMed ID: 38192142
[TBL] [Abstract][Full Text] [Related]
39. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
40. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
